Program
rentosertib
Also written as “INS018_055” and “INS018_055 tablets”.
Its studies are mostly in Idiopathic Pulmonary Fibrosis, led by InSilico Medicine Hong Kong.
Furthest: phase 3, since Jun 22, 20264 company-led studies, 2 open or runningNext primary completion: Oct 30, 2029 (phase 3)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| InSilico Medicine Hong Kong | 42 open or running | phase 3since Jun 22, 2026 | Nov 17, 2021 | Oct 30, 2029phase 3 · NCT07687459 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 17, 2021First study: phase 1 study in Idiopathic Pulmonary FibrosisFirst studyNCT05154240 · 78 enrolled · New Zealand
- Jun 28, 2023Phase 2 study in Idiopathic Pulmonary FibrosisNCT05938920 · 71 enrolled · China
- Jul 27, 2023Phase 2 study in Idiopathic Pulmonary FibrosisNCT05975983 · 40 planned · United States
- Jun 22, 2026Phase 3 study in Idiopathic Pulmonary FibrosisPhase 3 reachedNCT07687459 · 320 planned · China
Ahead
- Oct 30, 2029Primary completion: phase 3 study in Idiopathic Pulmonary FibrosisNCT07687459
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07687459Idiopathic Pulmonary Fibrosis · China | 3 | Recruiting | Oct 30, 2029 | 320 |
| NCT05975983Idiopathic Pulmonary Fibrosis · United States | 2 | Recruiting | Feb 28, 2026 | 40 |
| NCT05938920Idiopathic Pulmonary Fibrosis · China | 2 | Completed | Aug 8, 2024 | 71 |
| NCT05154240Idiopathic Pulmonary Fibrosis · New Zealand | 1 | Completed | Dec 2, 2022 | 78 |
How it is read
Names in the registry
- “INS018_055”, 3 entries
- “INS018_055 tablets”, 1 entry
Conditions, from the studies’ own filings
- Idiopathic Pulmonary Fibrosis, 4 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.